Skip to main content
OpenTrials
Completed

NCT Number: NCT01165177

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 50 years.

Two studies [ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229)] are being conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. The protocol posting of study ZOSTER-022 also deals with the outcome measures related to the pooled analysis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Herpes Zoster DNA Virus Infections Herpesviridae Infections Infections Varicella Zoster Virus Infection Virus Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

GSK Investigational Site, Glebe, New South Wales, Australia

Loading trial locations.

About this study

This protocol summary has been updated following Protocol Amendment 4 changes to study objectives and endpoints and the analyses of the objectives in 2 steps.

Step 1 will include analyses of the following objectives of ZOSTER-006 (NCT01165177): all HZ VE objectives and all reactogenicity/safety and immunogenicity objectives. At step 2, all objectives of study ZOSTER-006 (NCT01165177) will be analyzed. Objectives already analyzed at step 1 will be re-analyzed (confirmatory descriptive in case of inferential analysis at step 1 or descriptive analysis otherwise). At step 2, pooled analyses of studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) are planned; overall PHN VE in subjects ≥ 70 YOA, and other pre-specified endpoints will be analyzed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who the investigator believes will comply with the requirements of the protocol;
  • Written informed consent obtained from the subject;
  • A male or female aged 50 years or older at the time of the first vaccination;
  • Female subjects of non-childbearing potential may be enrolled in the study;

For this study population, non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.

OR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 days prior to vaccination, and has a negative urine pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series;

Exclusion criteria

  • Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period;
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product;
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy;
  • History of HZ;
  • Previous vaccination against varicella or HZ;
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation;
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study;
  • Receipt of immunoglobulins and/or any blood products within the 90 days preceding the first dose of study vaccine or planned administration during the study period;
  • Administration or planned administration of any other immunizations within 30 days before the first or second study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine;
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study;
  • Acute disease and/or fever at the time of enrollment;
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
  • Pregnant or lactating female;
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.

Treatment and study plan

Herpes Zoster vaccine GSK1437173A

Biological

Intramuscular injection

Placebo

Biological

Intramuscular injection

Primary outcomes

  1. Number of Subjects With Confirmed Herpes Zoster (HZ) Cases

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    Confirmed HZ cases during the study were assessed in the Modified Total Vaccinated Cohort (mTVc)

Secondary outcomes

  1. Number of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN)

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    The incidence of PHN was calculated using the modified total vaccinated chort.

  2. Number of Subjects With a Reduction of Duration of Severe 'Worst' HZ-associated Pain

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) questionnaire. The outcome assessed the duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the ZBPI in subjects with confirmed HZ. This analysis involved any subject reporting clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.

  3. Number of Subjects With Confirmed HZ Episode Related Mortality

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    The analysis focused on the number of subjects who died due to HZ

  4. Number of Subjects With HZ Related Complications

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    The analysis focused on the incidence of HZ complications in subjects with confirmed HZ

  5. Number of Subjects With Confirmed HZ Episode Related Hospitalizations

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    The analysis focused on confirmed HZ episode related hospitalizations.

  6. Number of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    The analysis focused on patients who experienced a reduction in duration of pain medication administered for HZ in subjects with confirmed HZ.

  7. Number of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    The analysis focused on subjects taking pain medication due to HZ

  8. Number of Days With Severe 'Worst' HZ-associated Pain.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' ZBPI questionnaire. This Outcome Measure was only assessed participants with confirmed HZ. This analysis involved any subject reporting ZBPI clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.

  9. Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    The analysis focused on confirmed HZ episode related hospitalizations and deaths.

  10. Number of Subjects With HZ Related Complications, by Complication Type

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    Complication types included HZ vasculitis, Disseminated Disease, Ophtalmic Disease, Neurologic Disease, Visceral Disease and Stroke. This Outcome Measure was only assessed participants with confirmed HZ.

  11. Distribution of Pain Medication Associated With HZ

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    The distribution of pain medication included 1 to 3 or more separate medications. This Outcome Measure was only assessed on participants with confirmed HZ.

  12. Number of Days of Pain Medication Associated With HZ

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    The analysis was performed on subjects with a confirmed HZ episode

  13. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Time frame: During the 7-day (Days 0-6) post-vaccination period

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.

  14. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Time frame: Within the 7-day (Days 0-6) post-vaccination period

    Assessed solicited general symptoms were fatigue, GI (gastrointestinal) symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), fever [defined as oral, axillary, rectal or tympanic temperature equal to or above 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = temperature> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

  15. Number of Subjects With Any and Grade 3 Symptoms (Solicited and Unsolicited)

    Time frame: Within the 7-day (Days 0-6) post-vaccination period

    Number of subjects with any and grade 3 solicited and unsolicited symptoms were tabulated

  16. Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all subjects

  17. Number of Subjects With AEs With Any and Related Medically Attended Visit

    Time frame: From Month 0 to Month 8 post-vaccination

    Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits in all subjects.

  18. Number of Subjects With Unsolicited Adverse Events (AEs)

    Time frame: Within 30 days (Days 0 - 29) after each vaccination

    Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

  19. Number of Subjects With Serious Adverse Events (SAEs)

    Time frame: Within the 30-day (Days 0-29) post-vaccination period, up to Month 14 and up to study end (3 to 5 year period following Day 0)

    Occurrence and relationship to vaccination of all SAEs in all subjects. Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  20. Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine

    Time frame: During the entire study period (3 to 5 year period following Day 0)

    The number of subjects with SAEs related to study participation or to a concurrent GSK medication/vaccine were tabulated

  21. Number of Subjects With Fatal SAEs

    Time frame: During the entire study period (3 to 5 years following day 0)

    Number of subjects with fatal SAEs during the entire study period were tabulated

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Efficacy, Safety, and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older

Important dates

Study start
2010
Primary completion
2014
Study completion
2015
First posted
Jul 19, 2010
Registry last updated
Feb 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.